



On floor Seminar Agenda

Speakers:

Andre Markmann, Vice President Business Development, **Biotechpharma**
Angès Menut, Programme Manager & Business Development, **MiMabs**
Cathie Miller, Director of Product Marketing, **BioIVT**
Debby Kruijssen, Head of Contract Research, **ImmunoPrecise**
Emma Zhang, Marketing Director, **Genscript Biotech**
Ferran Sanchez, Market Development Manager, **SCIEX**
Gautier Robin, Co-Founder, **iMab**
Kerstin Pohl, Senior Support Specialist, **SCIEX**
Marc Schulte, Sales & Business Development Manager, **Eurofins Pharma Discovery Services**
Marcus Mreyen, Director, Business Development, **Protagen**
Maxime Lestra, Life Science Sales Representative, **RD Biotech**
Michael Herbert, Sales and Marketing Director, **Biotem**
Michael Schwenkert, Technical Sales Manager – Custom Antibodies, **Bio-Rad Laboratories**
Philippe Funrock, CEO, **Proteogenix**
Ravindra Chaudhari, Global Sales and Business Development Manager, **Promise Advances**
Representative, **Proteomics**
Representative, **Envigo**
Representative, **Imuneed**
Stéphane Martinez, Corporate Product Manager, **Cisbio**
Stewart McNaull, Senior VP, Business Development, **KBI Biopharma**
Tanguy Fortin, CEO/Founder, **Anaquant**
Ulrich Mayer, Technical Sales Specialist – Custom Antibodies, **Bio-Rad Laboratories**
Ulrich Rant, Chief Executive Officer, **Dynamic Biosensors**
Vincent Puard, CEO, **MabSilico**

(23)

Day 1 – 29th October 2018

<p>10:30 – 11:10</p>	<p>Analytics and characterisation</p> <ul style="list-style-type: none"> • How can we use tools and knowledge to speed innovation? • Novel technologies, proven techniques and risk-based approaches • Characterising new modalities • Analysing structure-function <p>Moderated by Marcus Mreyen, Director, Business Development, Protagen</p> <p>Cathie Miller, Director of Product Marketing, BioIVT Ulrich Mayer, Technical Sales Specialist – Custom Antibodies, Bio-Rad Laboratories Representative, Imuneed Stewart McNaull, Senior VP, Business Development, KBI Biopharma Kerstin Pohl, Senior Support Specialist, SCIEX</p>
<p>12:45 – 13:25</p>	<p>Drug discovery technologies</p> <ul style="list-style-type: none"> • Discussion of modern therapeutics antibody drug discovery technologies • How can technologies address the challenges of drug discovery? <ul style="list-style-type: none"> • Non-specific targeting of antigens • Toxicity • Limitations in biological activity • Cost <p>Michael Schwenkert, Technical Sales Manager – Custom Antibodies, Bio-Rad Laboratories Ulrich Rant, Chief Executive Officer, Dynamic Biosensors Debby Kruijzen, Head of Contract Research, ImmunoPrecise Stéphane Martinez, Corporate Product Manager, Cisbio Gautier Robin, Co-Founder, iMab Vincent Puard, CEO, MabSilico Marc Schulte, Sales & Business Development Manager, Eurofins Pharma Discovery Services</p>
<p>13:30 – 14:10</p>	<p>CMC and developability of biologics</p> <ul style="list-style-type: none"> • Control and characterisation of complex molecules • How to achieve the right formulation, stability and consistency for effective scale up and manufacturing • Continues process improvements and reducing costs through outsourcing • Meeting regulatory requirements <p>Representative, Envigo Representative, Imuneed Tanguy Fortin, CEO/Founder, Anaquant</p>
<p>15:40 – 16:20</p>	<p>Antibody production</p> <ul style="list-style-type: none"> • How can technology streamline the production of antibodies from antigen production, through to antibody/protein characterisation • Solutions to make antibody production quicker, cheaper and more efficient • Hybridoma technology vs phage-display technology <p>Andre Markmann, Vice President Business Development, Biotechpharma Angès Menut, Programme Manager & Business Development, MiMabs Emma Zhang, Marketing Director, Genscript Biotech</p>

	Representative, Eurofins
Day 2 – 30 th October 2018	
10:30 – 11:10	<p>Bioprocessing for biologics</p> <ul style="list-style-type: none"> • The challenges of disruptive technologies in bioprocessing • Overcoming challenges with upstream and downstream processing • Continuous processing • Issues with formulation, fill and finish <p>Stewart McNaull, Senior VP, Business Development, KBI Biopharma</p>
13:10 – 13:50	<p>Mass spectrometry</p> <ul style="list-style-type: none"> • Mass spectrometry advances and the effects on biologic development • Advances and challenges in analytical characterisation • Workflow limitations of mass spec, and continuous improvement <p>Moderated by Marcus Mreyen, Director, Business Development, Protagen</p> <p>Ferran Sanchez, Market Development Manager, SCIEX Ravindra Chaudhari, Global Sales and Business Development Manager, Promise Advances Representative, Proteomics</p>
13:55 – 14:35	<p>Sequencing & screening</p> <ul style="list-style-type: none"> • Challenges associated with antibody sequencing and screening • Innovations and technology set to streamline sequencing and screening • How using a CRO can speed up the discovery process <p>Maxime Lestra, Life Science Sales Representative, RD Biotech</p>
16:05 – 16:45	<p>Antibody production</p> <ul style="list-style-type: none"> • How can technology streamline the production of antibodies from antigen production, through to antibody/protein characterisation • Solutions to make antibody production quicker, cheaper and more efficient • Hybridoma technology vs phage-display technology <p>Representative, Imuneed Michael Herbert, Sales and Marketing Director, Biotem Philippe Funfrock, CEO, Proteogenix Stewart McNaull, Senior VP, Business Development, KBI Biopharma</p>
Day 3 – 31 st October 2018	
10:30 – 11:10	
13:10 – 13:50	
End of on floor programme	